Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma

• DOI: 10.1159/000342425
• Publication Date: 2012-10-19T15:40:07Z
• Authors: Ronald Koschny; Daniel Gotthardt; Christiane Koehler; Dirk Jaeger; Wolfgang Stremmel; Tom M. Ganten
• Keywords: Aged, 80 and over; Diarrhea; Liver Cirrhosis; Male; Niacinamide; Carcinoma, Hepatocellular; Pyridines; Phenylurea Compounds; Benzenesulfonates; Liver Neoplasms; Nausea; Middle Aged; Sorafenib; Skin Diseases; 3. Good health; Survival Rate; 03 medical and health sciences; 0302 clinical medicine; Humans; Female; Prospective Studies; Aged; Follow-Up Studies

<b><i>Objective:</i></b> This study was performed to identify clinical predictors for better survival in patients with advanced hepatocellular carcinoma (HCC) under sorafenib treatment. <b><i>Methods:</i></b> Between December 2007 and January 2010, 46 HCC were treated until significant tumor progression or intolerable toxicity. We prospectively collected baseline data as well on the incidence severity of toxic side effects be correlated progression-free overall (OS), respectively. <b><i>Results:</i></b> Only 26.1% (n = 12) tolerated without requiring dose reduction. The most frequent grade 3 toxicities diarrhea (32.6%), hand-foot skin reaction (13.0%), fatigue (4.3%), nausea/vomiting (2.2%). Eastern Cooperative Oncology Group performance status (p 0.034) portal vein infiltration 0.021) significantly OS. Furthermore, we found a correlation between OS appearance 2 median actuarial 11.8 months (95% CI 6.9–16.6) compared 4.2 0 1 0.0–9.1; p 0.009). In contrast, did neither correlate nor <b><i>Conclusion:</i></b> Appearance indicates undergoing